Kuros Biosciences AG

SWX:KURN Stock Report

Market Cap: CHF 1.1b

Kuros Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KURN?
Owner TypeNumber of SharesOwnership Percentage
Institutions6,062,66915.5%
Individual Insiders9,403,77924%
General Public23,686,38060.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 39.11% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24%
C. Oomen
9,403,779CHF 257.3m13.3%no data
3.21%
BlackRock, Inc.
1,257,834CHF 34.4m0%no data
2.82%
UBS Asset Management AG
1,104,870CHF 30.2m0%no data
2.71%
Global Fund Advisors Limited
1,060,233CHF 29.0m-51%98.21%
2.28%
Joh. Berenberg, Gossler & Co. KG
890,746CHF 24.4m212%1.29%
1.01%
Deka Investment GmbH
394,500CHF 10.8m34%0.01%
0.46%
ZKB Asset Management
180,399CHF 4.9m0%0.01%
0.4%
Zürcher Kantonalbank
155,913CHF 4.3m0%0.03%
0.28%
3V Asset Management AG
110,000CHF 3.0m0%1.87%
0.26%
WCM Investment Management, LLC
103,674CHF 2.8m0%no data
0.24%
Causeway Capital Management LLC
95,409CHF 2.6m0%0.01%
0.23%
Valiant Bank AG
91,201CHF 2.5m0%0.25%
0.18%
Union Bancaire Privée, UBP SA
70,077CHF 1.9m0%0.04%
0.15%
Eaton Vance Management
57,965CHF 1.6m0%no data
0.14%
Lupus alpha Investment GmbH
53,000CHF 1.5m0%0.44%
0.1%
Rhenman & Partners Asset Management AB
40,707CHF 1.1m0%0.12%
0.1%
BCV Asset Management
40,000CHF 1.1m0%0.02%
0.097%
State Street Global Advisors, Inc.
37,846CHF 1.0m10.9%no data
0.078%
American Century Investment Management Inc
30,634CHF 838.1k0%no data
0.069%
Migrosbank Asset Management
26,985CHF 738.3k0%0.07%
0.061%
Aquila & Co. AG
23,700CHF 648.4k0%0.65%
0.057%
The Vanguard Group, Inc.
22,133CHF 605.6k0%no data
0.054%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
21,252CHF 581.5k-47.5%no data
0.054%
Geode Capital Management, LLC
20,981CHF 574.1k3.89%no data
0.048%
Baader Bank Aktiengesellschaft
18,600CHF 508.9k0%0.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/14 17:42
End of Day Share Price 2025/11/14 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kuros Biosciences AG is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research